AbbVie Receives Approval for Rinvoq to Treat Giant Cell Arteritis in Japan AbbVie announces additional approval for Rinvoq in Japan, providing a new treatment option for adults with giant cell arteritis who have not responded to existing therapies.

AbbVie Receives Approval for Rinvoq to Treat Giant Cell Arteritis in Japan #Japan #AbbVie #RINVOQ #Giant_Cell_Arteritis #Minato_City

RINVOQ® Gains FDA Approval for Giant Cell Arteritis: A New Hope for Patients AbbVie's RINVOQ® has received FDA approval as the first oral treatment for Giant Cell Arteritis, providing a new hope for patients seeking relief.

RINVOQ® Gains FDA Approval for Giant Cell Arteritis: A New Hope for Patients #United_States #AbbVie #North_Chicago #Giant_Cell_Arteritis #RINVOQ®

New EU Approval for Rinvoq as Treatment for Giant Cell Arteritis in Adults AbbVie has received EU approval for Rinvoq, making it the first oral JAK inhibitor for adult patients with giant cell arteritis, offering new hope for better treatment outcomes.

New EU Approval for Rinvoq as Treatment for Giant Cell Arteritis in Adults #None #AbbVie #RINVOQ #Giant_Cell_Arteritis

AbbVie Receives EU Approval for RINVOQ® to Treat Giant Cell Arteritis AbbVie has announced the European Commission's approval for RINVOQ, the first oral JAK inhibitor for adults with giant cell arteritis, providing a new therapeutic option.

AbbVie Receives EU Approval for RINVOQ® to Treat Giant Cell Arteritis #None #AbbVie #RINVOQ #Giant_Cell_Arteritis